A new clinical trial is investigating whether high doses of vitamin B3 (niacin) could help improve outcomes for patients with glioblastoma, one of the most aggressive and difficult-to-treat brain cancers. Researchers discovered that niacin may reactivate immune cells that tumors typically suppress, enabling the body’s natural defenses to better recognize and attack cancer cells. Early findings have shown encouraging results, with patients experiencing longer progression-free survival than normally expected. While larger studies are needed to confirm the benefits, the research highlights the potential of using a widely available vitamin as part of an innovative strategy to strengthen cancer immunotherapy and improve patient outcomes.
Read more at ScienceDaily